TG THERAPEUTICS INC (TGTX)
US88322Q1085 - Common Stock
Taking everything into account, TGTX scores 4 out of 10 in our fundamental rating. TGTX was compared to 610 industry peers in the Biotechnology industry. While TGTX seems to be doing ok healthwise, there are quite some concerns on its profitability. TGTX is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year TGTX has reported negative net income.
In the past year TGTX has reported a negative cash flow from operations.
TGTX had negative earnings in each of the past 5 years.
In the past 5 years TGTX always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -7.82%, TGTX belongs to the top of the industry, outperforming 89.53% of the companies in the same industry.
TGTX has a better Return On Equity (-15.72%) than 87.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.82% | ||
| ROE | -15.72% | ||
| ROIC | N/A |
ROA(3y)-79.6%
ROA(5y)-110.47%
ROE(3y)-179.67%
ROE(5y)-341.94%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TGTX's Gross Margin of 96.68% is amongst the best of the industry. TGTX outperforms 96.51% of its industry peers.
TGTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 96.68% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TGTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TGTX has been increased compared to 1 year ago.
The number of shares outstanding for TGTX has been increased compared to 5 years ago.
The debt/assets ratio for TGTX is higher compared to a year ago.
2.2 Solvency
TGTX has an Altman-Z score of 3.58. This indicates that TGTX is financially healthy and has little risk of bankruptcy at the moment.
TGTX has a Altman-Z score of 3.58. This is in the better half of the industry: TGTX outperforms 76.41% of its industry peers.
A Debt/Equity ratio of 0.60 indicates that TGTX is somewhat dependend on debt financing.
TGTX's Debt to Equity ratio of 0.60 is on the low side compared to the rest of the industry. TGTX is outperformed by 76.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.6 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.58 |
ROIC/WACCN/A
WACC11.1%
2.3 Liquidity
TGTX has a Current Ratio of 5.53. This indicates that TGTX is financially healthy and has no problem in meeting its short term obligations.
TGTX has a Current ratio (5.53) which is in line with its industry peers.
TGTX has a Quick Ratio of 4.95. This indicates that TGTX is financially healthy and has no problem in meeting its short term obligations.
TGTX has a Quick ratio (4.95) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.53 | ||
| Quick Ratio | 4.95 |
3. Growth
3.1 Past
TGTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 84.18%, which is quite impressive.
Looking at the last year, TGTX shows a very strong growth in Revenue. The Revenue has grown by 3696.00%.
TGTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 79.43% yearly.
EPS 1Y (TTM)84.18%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q380.77%
Revenue 1Y (TTM)3696%
Revenue growth 3Y164.95%
Revenue growth 5Y79.43%
Revenue growth Q2Q165700%
3.2 Future
The Earnings Per Share is expected to grow by 32.71% on average over the next years. This is a very strong growth
TGTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 198.28% yearly.
EPS Next Y102.45%
EPS Next 2Y41.67%
EPS Next 3Y33.93%
EPS Next 5Y32.71%
Revenue Next Year5274.83%
Revenue Next 2Y665.16%
Revenue Next 3Y348.02%
Revenue Next 5Y198.28%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
TGTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 1541.18, the valuation of TGTX can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of TGTX indicates a rather cheap valuation: TGTX is cheaper than 93.02% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 20.05, TGTX is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 1541.18 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
TGTX's earnings are expected to grow with 33.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.67%
EPS Next 3Y33.93%
5. Dividend
5.1 Amount
TGTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TG THERAPEUTICS INC
NASDAQ:TGTX (12/8/2023, 7:19:12 PM)
After market: 15.68 -0.04 (-0.25%)15.72
-0.31 (-1.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.38B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 1541.18 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.82% | ||
| ROE | -15.72% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 96.68% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.6 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.53 | ||
| Quick Ratio | 4.95 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)84.18%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y102.45%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)3696%
Revenue growth 3Y164.95%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y